Testing XKH001 injection for COPD with frequent flare-ups
Part of Lungs & breathing clinical trials.
This study tests a new injection called XKH001 to see if it helps people with COPD (chronic lung disease) who have frequent flare-ups despite using regular inhaler medications. The goal is to reduce how often flare-ups happen and improve breathing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 40–80 years old
- Diagnosed with COPD for at least 12 months with moderate-to-severe airflow limitation
- Current or former smoker with at least 10 pack-years of smoking history
- Had at least 2 moderate or 1 severe COPD flare-up in the past year requiring steroids, antibiotics, or hospitalization
- Taking inhaled maintenance therapy (dual or triple combination inhalers) for at least 3 months, with stable dose for at least 1 month
- Blood eosinophil count of at least 150/μL (a type of white blood cell)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new inhaled medication, HRS-9821, in healthy people and in people with COPD. For COPD patients, the goal is to see how safe and well-tolerated multiple doses are, which could lead to a new treatment option.
This trial tests an injection called RC1416 for people with moderate-to-severe COPD who still have flare-ups despite using triple inhaler therapy. It may help reduce those flare-ups and improve breathing.
This trial tests two forms of a new medication (HSK39004) in people with COPD. The goal is to see if they help improve breathing and are safe. Eligible participants must be between 40 and 80, have moderate to severe COPD, and be able to stop other COPD treatments during the study.
This trial tests a new inhaled drug, HSK39004, to see if it safely improves breathing and quality of life in people with moderate to severe COPD. You may join if you are between 40 and 80, have a COPD diagnosis with certain lung function results, and have at least some shortness of breath with daily activities.
This trial tests an experimental injection called JKN2401 for people with COPD. It aims to see if it helps reduce flare-ups and improve breathing compared to standard care.
This study tests a new injectable medicine called CM310 for people with moderate to severe COPD who have chronic bronchitis and frequent flare-ups, despite using standard inhalers. It aims to see if CM310 can reduce flare-ups and improve breathing by targeting a specific type of inflammation.
Hear when a new COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.